LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

44.57 -0.4

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

43.32

Максимум

45.18

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+24.2% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	71M 3.3B
Предишно отваряне	44.97
Предишно затваряне	44.57

Настроения в новините

By Acuity

50%

167 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.02.2026 г., 23:25 ч. UTC

Горещи акции

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25.02.2026 г., 23:15 ч. UTC

Печалби

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25.02.2026 г., 23:54 ч. UTC

Пазарно говорене

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25.02.2026 г., 23:47 ч. UTC

Печалби

Ferrovial 4Q Net EUR197M >FER.MC

25.02.2026 г., 23:45 ч. UTC

Печалби

Ferrovial 4Q Rev EUR2.72B >FER.MC

25.02.2026 г., 23:42 ч. UTC

Печалби

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Company's Business Operations Remain Normal >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY EPS CNY47.67 >TCOM

25.02.2026 г., 23:06 ч. UTC

Печалби

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25.02.2026 г., 23:01 ч. UTC

Печалби

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25.02.2026 г., 23:00 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

25.02.2026 г., 23:00 ч. UTC

Пазарно говорене

Печалби

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25.02.2026 г., 22:56 ч. UTC

Пазарно говорене

Печалби

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25.02.2026 г., 22:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25.02.2026 г., 22:40 ч. UTC

Пазарно говорене

Печалби

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25.02.2026 г., 22:40 ч. UTC

Печалби

Karoon Energy Says Search for New CFO Well Advanced

25.02.2026 г., 22:39 ч. UTC

Печалби

Karoon Energy Says CFO Ray Church to Leave Company

25.02.2026 г., 22:39 ч. UTC

Печалби

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25.02.2026 г., 22:38 ч. UTC

Печалби

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

24.2% нагоре

12-месечна прогноза

Среден 55.63 USD 24.2%

Висок 66 USD

Нисък 44 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

167 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.